FARN: Bexmarilimab reports 45% remission in high-risk MDS
FARN said its bexmarilimab achieved 45% remission in high-risk MDS, and that funding has been secured for pivotal trials.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.